Literature DB >> 19634191

Making and circumventing tolerance to cancer.

Thomas Kammertoens1, Thomas Blankenstein.   

Abstract

The interactions between cancer and immune cells are complex. Even though the mutations that cause cancer can create new antigens that are potentially "visible" to T cells, in most experimental model systems the growth of tumors is accompanied by induction of T-cell tolerance towards the tumor. How tolerance to tumors is induced and how tolerance can be broken by immunotherapy have been a main focus in cancer immunology. Here, we discuss experimental models used in cancer immunology. We argue that, while it is obviously easy for tumors to induce tolerance, it should be as easy to circumvent tolerance by the adoptive transfer of tumor-antigen-reactive T cells. Effective adoptive T-cell therapy has become feasible by methods to identify TCR against tumor-associated (self-) antigens with high affinity and to graft a new antigen specificity to patients' T cells by TCR gene transfer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19634191     DOI: 10.1002/eji.200939612

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  8 in total

1.  Cell-based immunotherapy of prion diseases by adoptive transfer of antigen-loaded dendritic cells or antigen-primed CD(4+) T lymphocytes.

Authors:  Claude Carnaud; Véronique Bachy
Journal:  Prion       Date:  2010-04-04       Impact factor: 3.931

Review 2.  Rebalancing immune specificity and function in cancer by T-cell receptor gene therapy.

Authors:  Akshata Udyavar; Terrence L Geiger
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2010-08-01       Impact factor: 4.291

3.  A combination of local inflammation and central memory T cells potentiates immunotherapy in the skin.

Authors:  Salvatore Fiorenza; Tony J Kenna; Iain Comerford; Shaun McColl; Raymond J Steptoe; Graham R Leggatt; Ian H Frazer
Journal:  J Immunol       Date:  2012-11-09       Impact factor: 5.422

Review 4.  Redirecting the immune response: role of adoptive T cell therapy.

Authors:  Anna Mondino; Valérie Dardalhon; Rodrigo Hess Michelini; Severine Loisel-Meyer; Naomi Taylor
Journal:  Hum Gene Ther       Date:  2010-05       Impact factor: 5.695

Review 5.  Immunology in the clinic review series; focus on cancer: double trouble for tumours: bi-functional and redirected T cells as effective cancer immunotherapies.

Authors:  L A Marr; D E Gilham; J D M Campbell; A R Fraser
Journal:  Clin Exp Immunol       Date:  2012-02       Impact factor: 4.330

6.  MHC-class I-restricted CD4 T cells: a nanomolar affinity TCR has improved anti-tumor efficacy in vivo compared to the micromolar wild-type TCR.

Authors:  Carolina M Soto; Jennifer D Stone; Adam S Chervin; Boris Engels; Hans Schreiber; Edward J Roy; David M Kranz
Journal:  Cancer Immunol Immunother       Date:  2012-08-25       Impact factor: 6.968

7.  Genetically modified T cells targeting neovasculature efficiently destroy tumor blood vessels, shrink established solid tumors and increase nanoparticle delivery.

Authors:  Xinping Fu; Armando Rivera; Lihua Tao; Xiaoliu Zhang
Journal:  Int J Cancer       Date:  2013-07-11       Impact factor: 7.396

8.  The tumor targeted superantigen ABR-217620 selectively engages TRBV7-9 and exploits TCR-pMHC affinity mimicry in mediating T cell cytotoxicity.

Authors:  Gunnar Hedlund; Helena Eriksson; Anette Sundstedt; Göran Forsberg; Bent K Jakobsen; Nicholas Pumphrey; Karin Rödström; Karin Lindkvist-Petersson; Per Björk
Journal:  PLoS One       Date:  2013-10-23       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.